# Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.

> **NCT03158688** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 466 (actual)

## Conditions studied

- Relapsed Multiple Myeloma
- Refractory Multiple Myeloma

## Interventions

- **DRUG:** Dexamethasone
- **DRUG:** Daratumumab
- **DRUG:** Carfilzomib

## Key facts

- **NCT ID:** NCT03158688
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-13
- **Primary completion:** 2019-07-14
- **Final completion:** 2022-04-15
- **Target enrollment:** 466 (ACTUAL)
- **Last updated:** 2025-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03158688

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03158688, "Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03158688. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*